Results 11 to 20 of about 411,149 (312)

Immunotherapy of lung cancer: An update [PDF]

, 2006
In Germany lung cancer is the leading cause of cancer-associated death in men. Surgery, chemotherapy and radiation may enhance survival of patients suffering from lung cancer but the enhancement is typically transient and mostly absent with advanced ...
Hatz, R. A., Jauch, Karl-Walter, van den Engel, N.K., Fox, B.A., Grützner, S., Hatz, R.A., Rüttinger, D., Fox, B. A., Jauch, K.-W., Winter, H., van den Engel, N. K., Schendel, D. J., Pohlac, H., Pohla, H., Schlemmer, M., Schendel, D.J.   +15 more
core   +1 more source

The Renewal of Cancer Immunotherapy

, 2023
Cancer immunotherapy embraces many current, promising therapeutic approaches to eradicate tumors by activating host antitumor activity [...
Jenny Bulgarelli, Laura Ridolfi, Sara Pignatta, Massimiliano Petrini   +3 more
core   +1 more source

Recent Advances and Challenges in Cancer Immunotherapy

, 2022
SIMPLE SUMMARY: Immunotherapy helps a person’s immune system to target tumor cells. Recent advances in cancer immunotherapy, including immune checkpoint inhibition, chimeric antigen receptor T-cell therapy and cancer vaccination, have changed the ...
Yiping Yang, Peterson, Chelsea, Denlinger, Nathan, Chelsea Peterson, Nathan Denlinger, Yang, Yiping   +5 more
core   +1 more source

Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again

Genome Medicine, 2018
For at least 300 years the immune system has been targeted to improve human health. Decades of work advancing immunotherapies against infection and autoimmunity paved the way for the current explosion in cancer immunotherapies.
Samantha L. Bucktrout, Jeffrey A. Bluestone, Fred Ramsdell   +2 more
doaj   +1 more source

Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer

Scientific Reports, 2021
Despite recent progress in therapeutic strategies, prognosis of metastatic triple-negative breast cancer (TNBC) remains dismal. Evidence suggests that the induction and activation of tumor-residing conventional type-1 dendritic cells (cDC1s) is critical ...
Toshihiro Yokoi, Takaaki Oba, Ryutaro Kajihara, Scott I. Abrams, Fumito Ito   +4 more
doaj   +1 more source

Advancing Cancer Immunotherapy: From Molecular Mechanisms to Clinical Applications

, 2023
In recent years, cancer immunotherapy research has made remarkable progress, completely transforming the cancer treatment landscape [...
Timothy Starr, Subbaya Subramanian, Xianda Zhao   +2 more
core   +1 more source

ERAP1 overexpression in HPV-induced malignancies: A possible novel immune evasion mechanism

OncoImmunology, 2017
Immune evasion of tumors poses a major challenge for immunotherapy. For human papillomavirus (HPV)-induced malignancies, multiple immune evasion mechanisms have been described, including altered expression of antigen processing machinery (APM) components.
Alina Steinbach, Jan Winter, Miriam Reuschenbach, Renata Blatnik, Alexandra Klevenz, Miriam Bertrand, Stephanie Hoppe, Magnus von Knebel Doeberitz, Agnieszka K. Grabowska, Angelika B. Riemer   +9 more
doaj   +1 more source

Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model

OncoImmunology, 2019
Therapeutic vaccination as a treatment option for HPV-induced cancers is actively pursued because the two HPV proteins E6 and E7 represent ideal targets for immunotherapy, as they are non-self and expressed in all tumor stages.
Sebastian Kruse, Marleen Büchler, Philipp Uhl, Max Sauter, Philipp Scherer, Tammy C.T. Lan, Samantha Zottnick, Alexandra Klevenz, Ruwen Yang, Frank Rösl, Walter Mier, Angelika B. Riemer   +11 more
doaj   +1 more source

Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma

Frontiers in Pharmacology, 2023
Introduction: This study aimed to identify immune mediators, including cytokines, chemokines, and growth factors, in the plasma for predicting treatment efficacy and immune-related adverse events (irAEs) in advanced urothelial carcinoma (aUC) treated ...
Yosuke Shibata, Takeshi Kishida, Taku Kouro, Taku Kouro, Feifei Wei, Feifei Wei, Yuka Igarashi, Yuka Igarashi, Hidetomo Himuro, Hidetomo Himuro, Takeaki Noguchi, Mitsuyuki Koizumi, Takahisa Suzuki, Kimito Osaka, Yusuke Saigusa, Tetsuro Sasada, Tetsuro Sasada   +16 more
doaj   +1 more source

Biomarkers in Cancer Immunotherapy [PDF]

Cancer Cell, 2015
Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate other aspects of the cancer ...
Schumacher, Ton N, Kesmir, Can, van Buuren, Marit M   +2 more
openaire   +4 more sources